ArticleFrontiers in microbiology2025
Comparative genomic insight into the myxobacterial carbohydrate-degrading potential.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Phylogenomic analysis and characterization of a novel metagenome-assembled genome from the Bay of Bengal and description of Candidatus Niobacter visakhapatnamensis gen. nov., sp. nov.Archives of microbiology · 2026Article
- Throughfall Reduction Other than Nitrogen Addition Threatens Soil Multifunctionality in a Subtropical Moso Bamboo Forest.Microorganisms · 2026Article
- Advancing cellulose degradation through synthetic biology: engineered pathways and microbial systems for sustainable biomass conversion.Journal of animal science and biotechnology · 2026Review
- PredatoryFrontiers in microbiology · 2026Article
- South African Myxococcota: an untapped resource for microbial ecolo gy and biotechnology.Applied microbiology and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxobacteria are an intriguing group of social-behavior-depicting microbes with unique physiological characteristics such as fruiting body formation, gliding motility, and predation, encompassing the largest genomes (>9 Mb) within the Eubacteria kingdom. These soil-dwelling organisms are crucial for lignocellulosic biomass degradation, which has both ecological and industrial significance. While previous studies have demonstrated polysaccharide deconstruction abilities in a few myxobacterial species, we aim to elucidate the distribution of their Carbohydrate Active Enzymes (CAZymes) domains per organism, with a focus on proteins involved in the catabolism of critical polysaccharides such as cellulose, lignin, xylan, starch, pectin, fructan, chitin, and dextran, across 61 high-quality sequenced myxobacterial genomes. Our findings reveal that 3.5% of the total genes at the median level have domains related to CAZyme functions across different myxobacterial families. Notably, family Archangiaceae (4.4%) and Myxococcaceae (3.7%) members exhibit the most significant genomic diversity and potential for degrading multiple substrates within lignocellulosic biomass. These plentiful CAZymes probably enable these majorly soil-harboring myxobacteria to breakdown various carbohydrate substrates into simpler biological molecules, which not only allow these organisms to sustain in poor-nutrient environments but also enable them to be critical players in carbon cycling and organic matter decomposition. Overall, it can be postulated that myxobacteria have an unexplored genomic potential that may play an integral role in the degradation of recalcitrant plant biomass, potentially influencing soil health and composition. This study further suggests the critical ecological importance of these CAZymes in sustaining the balance of terrestrial ecosystems and diverse industrial applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.